Health News

Vytal Options Celebrates the Grand Opening of Their Two Newest Dispensaries in State College, PA and Kennett Square, PA

HARRISBURG, Pa. – October 10, 2022 – (Newswire.com)

PA Options for Wellness (“PA Options for Wellness”, DBA “Vytal Options” or the “Company”), a leading provider of medical cannabis products in the Pennsylvania medical cannabis market, announced today the opening of two new medical marijuana dispensaries, bringing their retail footprint to a total of six locations throughout Pennsylvania.

The first of the two new dispensaries to open will be Kennett Square, located at 716 West Baltimore Pike in Delaware County, PA. The Kennett Square location will open to patients on Monday, Oct. 17. The second location, located in State College, at 1653 North Atherton Street, will open to patients on Monday, Oct. 31. Both locations will feature on-site consultations, curbside delivery and an interactive pre-order menu with each dispensary open six days a week, from 10 a.m. to 8 p.m.

“Vytal Options, a PA Options for Wellness medical marijuana dispensary, is excited to bring our excellent patient service as well as quality products to the State College and Kennett Square areas,” CEO and founder Thomas A. Trite said in a statement. “We were one of the first three medical marijuana Clinical Registrants approved by the Pennsylvania Department of Health to conduct research. After undergoing an extensive review process, we were selected by Penn State University and their College of Medicine to collaborate and research medical marijuana.”

To celebrate the grand openings, each location will kick off with a ribbon cutting ceremony at 9 a.m. ET, with members of the Chamber of Business, Penn State Research, and Balanced Veterans Network. A partnership with grower/processer FarmaceuticalRX has also been developed to support the dispensary openings.  A proprietary strain “Keystone OG” was created with the processing team at FarmaceuticalRX along with members of Vytal Options marketing and product development teams. The first 100 patients at each location will receive an exclusive, limited edition “Keystone OG” t-shirt to celebrate the collaboration. In addition, many of the state’s top Medical Marijuana Grower Processers will be on hand at both locations, educating patients and handing out promotional materials. In addition, PA Options for Wellness will commemorate its latest dispensary openings by making a charitable contribution to organizations within the State College and Kennett Square communities.

PA Options for Wellness proudly offers a curated selection of products across it’s brand portfolio, which includes byVytal, Mood, and Solventless. Patients can choose from a wide array of premium cannabis products, including full-spectrum RSO, access to a library of flower strains, solventless rosins, and their signature Troche sublingual. Vytal Options dispensaries will also offer top products from other highly requested brands in the Pennsylvania Medical Marijuana marketplace.

“Pennsylvania has become one of the fastest growing medical markets in the nation and we are proud to be able to widen access to patients across the state,” said Thomas A. Trite, Chief Executive Officer of PA Options for Wellness. “PA Options for Wellness will bring top-quality, innovative products to the medical market, meeting the demand of our patients while adhering to strict ethical standards. Providing therapeutic solutions, we focus on combining plant science and medicine to transform the lives of our patients.”  

In addition to PA Options for Wellness’ newest dispensary locations, the Company currently serves patients in the following areas: Harrisburg, Lancaster, Lansdale, and the Lehigh Valley.

About PA Options for Wellness

PA Options for Wellness was founded by Thomas A. Trite, PD, FASCP, in 2014 with the goal of creating a premier medical cannabis service model and becoming the leader in the emerging medical cannabis industry and cannabis research.

Headquartered in Harrisburg, PA Options for Wellness’ mission is to be the preferred provider of medical cannabis to qualified, approved patients through high-quality products, and dignified, professional service. The company is focused on research, patient outcomes and quality of life.

PA Options for Wellness is proud to have been awarded one of the first Pennsylvania Clinical Registrant licenses in June 2019 in collaboration with the Penn State College of Medicine. PA Options for Wellness also has a 65,000-square-foot grow/process facility that includes lab space and is located in Duncannon, Perry County.

PA Options for Wellness will bring top-quality, innovative products to the medical market, meeting the demand of our patients while adhering to strict ethical standards. Providing therapeutic solutions, we focus on combining plant science and medicine to transform the lives of our patients.

Media Inquires:
Samantha A. Alderfer
Director of Marketing & Business Development
PA Options for Wellness, Inc.
[email protected]
717-418-4362

Contact Information:

Samantha Alderfer

Director of Marketing & Business Development
[email protected]

Press Release Service
by
Newswire.com

Original Source:

PA Options for Wellness’ Medical Marijuana Presence Grows to Six ‘Vytal Options’ Dispensary Locations in Pennsylvania

As published in Frontiers in Pharmacology, the biopharmaceutical drug development firm’s sponsored research has identified and validated cannabinoid ratio-controlled, Minimum Essential Mixtures (MEM) for the treatment of Parkinson’s disease symptoms

LAS VEGAS – October 10, 2022 – (Newswire.com)

Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, has co-published a study in the journal Frontiers in Pharmacology that demonstrates the efficacy of its proprietary cannabinoid-containing, minimum essential mixtures (MEM) for the treatment of Parkinson’s disease (PD). There is a great clinical need for improved therapeutics, and the market for Parkinson’s disease treatments is expected to grow to $8.8 billion by 2026.

“Our drug discovery process has identified promising ratio-controlled mixtures of cannabis-inspired compounds for the treatment of Parkinson’s disease, which have proven effective at reducing Parkinsonian motor symptoms in an animal model of the disease,” said Dr. Andrea Small Howard, President, Chief Science Officer, and Director of Gb Sciences. “This study allows us to continue addressing unmet clinical needs through the development of novel plant-inspired drugs, and positions Gb Sciences as a contributor to the expanding world of novel PD therapeutics.”

For this Gb Sciences-sponsored study, the discovery research using cell models of Parkinson’s disease was performed at Chaminade University (Honolulu, Hawai’i, USA), and the MEM refinement and validation research was performed in a zebrafish model of Parkinson’s disease at the National Research Council of Canada (NRC). The study entitled “Identification of minimum essential therapeutic mixtures from Cannabis plant extracts by screening in cell and animal models of Parkinson’s disease“ was co-authored by Gb Sciences’ own President and Chief Science Officer Andrea Small-Howard and her collaborators Michael G. Morash, Jessica Nixon, and Lee Ellis from the National Research Council of Canada; Lori M.N. Shimoda and Helen Turner from Chaminade University of Honolulu; and Alexander J. Stokes from the University of Hawai’i at Manoa (Manoa, Hawai’i, USA).

The sequentially reductionist process implemented in this multi-site study preserves some of the entourage-like effects of whole plant extracts while achieving “relative” simplicity within MEM that is a requirement for obtaining the manufacturing and quality control advantages of single-ingredient drugs. This paper identifies promising minimal essential mixtures of cannabinoids based on a step-wise, strategic approach to reducing the complexity of the plant secondary metabolome. The sequential use of in silico, in vitro, and medium throughput in vivo experimental systems has generated refined, de-risked mixtures that can now be tested in additional, higher-cost, preclinical model systems of PD.

Gb Sciences’ Parkinson’s therapeutics are currently being tested in a rodent model of Parkinson’s disease at the University of Lethbridge, and these Parkinson’s MEM have been formulated as Oral Dissolving Tablets in preparation for human clinical trials. The Company is preparing for the final rounds of toxicology and pharmacology testing as required for filing an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration. 

To learn more about Gb Sciences, visit www.gbsciences.com.

About Gb Sciences and GbS Global Biopharma

Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary GbS Global Biopharma, Inc. The “plant-inspired” active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences’ intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 17 U.S. and 51 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences’ lead program for Parkinson’s disease is being prepared for a first-in-human clinical trial. Gb Sciences’ formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council of Canada. The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences’ productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com. 

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as “expects,” “intends,” “plans,” “may,” “could,” “should,” “anticipates,” “likely,” “believes” and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company’s business and financial and other results, are contained in the Company’s filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Contact Information:

Madeleine Moench
[email protected]

Press Release Service
by
Newswire.com

Original Source:

Gb Sciences Co-Publishes Study Demonstrating Efficacy of Its Proprietary Cannabinoid Mixtures for the Treatment of Parkinson’s Disease

Former President Donald Trump has called his successor Joe Biden an “enemy of the state” and accused President Biden of weaponising the FBI against him. The comments at a rally in Pennsylvania followed a raid on Trump’s Mar-a-Lago estate in Florida. It was to search for classified documents believed to have been removed from the […]

More families in America aren’t taking their children to get vaccinations. Experts say it could lead to the spread of measles, as has happened in Europe.
Neil and Catherine teach you how to use the English language the world’s media is us…

German-based biotechnology company BioNTech will establish a clinical scale research mRNA manufacturing facility in Australia, following an in-principle letter of intent signed with the Victorian Government.
…

P23 Labs Mental Health Awareness Weekend P23 Labs Mental Health Awareness Weekend
SAVANNAH, Ga. – October 7, 2022 …

A federal judge has granted former President Donald Trump’s request to appoint a “special master” to review materials that the FBI seized from Mar-a-Lago last month. CNN’s Sara Murray and Kara Scannell break down the judge&#821…

Support service in partnership with Mayor of Boston and Boston Public Health Commission

Day Engagement Center Day Engagement Center
…

LOS ANGELES – October 6, 2022 – (Newswire.com)

L-Nutra, Inc., the world’s leading nutrition technology company pioneering the discovery, design, and commercialization of novel nutrition solutions, today announced data in Cell Reports demonstrating the effects of fasting-mimicking diets (FMD) in animal models of Alzheimer’s disease and early human safety data. The study reports that FMD cycles reduce cognitive decline and Alzheimer’s disease pathology in mouse models. The early clinical data also suggest that FMD cycles are safe and feasible in a small group of Alzheimer’s patients. 

Alzheimer’s disease is a neurodegenerative disease characterized by progressive memory loss and a decline in quality of life and lifespan. An estimated 6.5 million Americans aged 65 and older live with Alzheimer’s dementia, and approximately 200,000 under age 65 have early-onset Alzheimer’s. The number of people affected globally by dementia is expected to increase to 152.8 million cases in 2050, primarily due to population aging. FDA-approved drugs for Alzheimer’s only temporarily improve or slow the deterioration of Alzheimer’s symptoms but do not generally affect disease progression. 

“L-Nutra is the world’s pioneering Nutri-Technology company bringing the revolutionary Fasting-Mimicking Technology (FMT) to transform the paradigm of care in four major chronic illnesses: cancer, diabetes, autoimmune diseases, and Alzheimer’s. With this published result, our FMT platform takes another bold step towards turning ‘food into medicine.’ Leveraging the rigor of the biotech industry, we are the leading nutrition company to have a nutrition solution with the potential to impact human longevity and the course of many chronic health conditions,” said Joseph Antoun, M.D., Ph.D., CEO and Chairman of L-Nutra, Inc. 

In this newly published paper, the lead author Professor Valter Longo at USC and investigators from other centers* show that cycles of FMT attenuate cognitive decline, reduce Alzheimer’s pathology and neuroinflammation, and promote neurogenesis and improve cognition in Alzheimer’s mouse models. In a pilot human trial included in the publication, the authors also show that the intervention is safe and feasible in a small group of Alzheimer’s patients.

“The patented FMT in previously published studies demonstrated a clear mechanism of action, supported by successful early human trials that showed safety and efficacy in diabetes and various forms of cancer. This exciting result in a neurodegenerative condition extends the finding that the FMT platform as a unique solution has an upstream and overarching systemic impact on the body,” said Dr. William Hsu, MD, Chief Medical Officer of L-Nutra, Inc. 

L-Nutra plans to evaluate further its FMT platform’s impact on driving various chronic conditions into remission or regression. For more information on L-Nutra and its revolutionary approach to targeting a broad spectrum of diseases, visit www.l-nutra.com or contact Dr. William Hsu, Chief Medical Officer, at [email protected].

*Collaborating centers include USC, IFOM, University of Genoa, UCLA, University of Illinois at Chicago, and University of Perugia.

About L-Nutra Inc.

L-Nutra is leading the discovery, design, and commercialization of novel nutri-programs with the mission of adding more life to human life. Current commercial products focus on wellness and healthy aging, including ProLon®, the first and only clinically tested 5-day fasting nutrition program designed to allow your body to enter a fasting state while still allowing you to consume nutrient-dense foods. L-Nutra created the 1-day fasting nutrition kit ProLon Reset™ and ProLon Intermittent Fasting Bar®, the first nutrition bar specifically designed and clinically tested to support intermittent fasting. Nutrition for Longevity® is L-Nutra’s science-backed, chef-curated meal program, featuring farm-to-table meals formulated to address the nutritional deficiencies in today’s commercially grown produce. For more info, visit https://l-nutra.com/.

Contact Information:

William Hsu

Chief Medical Officer
[email protected]

6176554394

Press Release Service
by
Newswire.com

Original Source:

L-Nutra Reports Fasting-Mimicking Diet Cycles Reduce Cognitive Decline and Pathology in Alzheimer’s Disease Models

FDA-Approved ShieldOn Precision Gloves Currently En Route to Los Angeles

UGTC Logo United Global Trading Corp logo.
LONG BEACH…